BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 29283062)

  • 1. Platelets Structure, Function and Modulator Capacity in Replacement Therapy.
    Moutinho B; Pinto B; Cardoso R; Botelho MC
    Cardiovasc Hematol Disord Drug Targets; 2017; 17(3):180-184. PubMed ID: 29283062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New strategies for the optimal use of platelet transfusions.
    Blajchman MA; Slichter SJ; Heddle NM; Murphy MF
    Hematology Am Soc Hematol Educ Program; 2008; ():198-204. PubMed ID: 19074082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fecal blood loss: A quantitative method of evaluating hemostasis in patients with thrombocytopenia.
    Slichter SJ; Gernsheimer T; LeBlanc R; Townsend-McCall D; Jones MK; Cuaron L; Bolgiano D
    Transfusion; 2021 Feb; 61(2):393-403. PubMed ID: 33166412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation.
    Estcourt L; Stanworth S; Doree C; Hopewell S; Murphy MF; Tinmouth A; Heddle N
    Cochrane Database Syst Rev; 2012 May; (5):CD004269. PubMed ID: 22592695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The platelet-refractory bone marrow transplant patient: prophylaxis and treatment of bleeding.
    Benson K; Fields K; Hiemenz J; Zorsky P; Ballester O; Perkins J; Elfenbein G
    Semin Oncol; 1993 Oct; 20(5 Suppl 6):102-9. PubMed ID: 8211211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylactic platelet transfusion for haemorrhage after chemotherapy and stem cell transplantation.
    Stanworth SJ; Hyde C; Heddle N; Rebulla P; Brunskill S; Murphy MF
    Cochrane Database Syst Rev; 2004 Oct; (4):CD004269. PubMed ID: 15495093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neonatal Platelet Transfusions and Future Areas of Research.
    Sola-Visner M; Bercovitz RS
    Transfus Med Rev; 2016 Oct; 30(4):183-8. PubMed ID: 27282660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogen-reduced platelets for the prevention of bleeding.
    Butler C; Doree C; Estcourt LJ; Trivella M; Hopewell S; Brunskill SJ; Stanworth S; Murphy MF
    Cochrane Database Syst Rev; 2013 Mar; (3):CD009072. PubMed ID: 23543569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet transfusion for patients with cancer.
    Fletcher CH; DomBourian MG; Millward PA
    Cancer Control; 2015 Jan; 22(1):47-51. PubMed ID: 25504278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients.
    Slichter SJ; Davis K; Enright H; Braine H; Gernsheimer T; Kao KJ; Kickler T; Lee E; McFarland J; McCullough J; Rodey G; Schiffer CA; Woodson R
    Blood; 2005 May; 105(10):4106-14. PubMed ID: 15692069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet transfusion therapy.
    Slichter SJ
    Hematol Oncol Clin North Am; 1990 Feb; 4(1):291-311. PubMed ID: 2179213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guidelines for platelet transfusions. British Committee for Standards in Haematology, Working Party of the Blood Transfusion Task Force.
    Murphy MF; Brozovic B; Murphy W; Ouwehand W; Waters AH
    Transfus Med; 1992 Dec; 2(4):311-8. PubMed ID: 1339584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of platelets in transfusion medicine.
    Brubaker DB
    J Am Osteopath Assoc; 1989 Dec; 89(12):1553-9. PubMed ID: 2621122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. POLYMORPHISM OF COLLECTION, TRANSFUSION AND EFFECTIVENESS OF DONOR PLATELETS CONCENTRATES.
    Gubanova MN; Ayupova RF; Zhiburt EB
    Anesteziol Reanimatol; 2017 Jan; 62(1):77-79. PubMed ID: 29932588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing platelet transfusion therapy.
    Heal JM; Blumberg N
    Blood Rev; 2004 Sep; 18(3):149-65. PubMed ID: 15183900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complement as an Immune Barrier in Platelet Transfusion Refractoriness.
    Meinke S; Karlström C; Höglund P
    Transfus Med Rev; 2019 Oct; 33(4):231-235. PubMed ID: 31679761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between platelet count and bleeding risk in thrombocytopenic patients.
    Slichter SJ
    Transfus Med Rev; 2004 Jul; 18(3):153-67. PubMed ID: 15248165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neonatal Transfusion Practice: When do Neonates Need Red Blood Cells or Platelets?
    Del Vecchio A; Franco C; Petrillo F; D'Amato G
    Am J Perinatol; 2016 Sep; 33(11):1079-84. PubMed ID: 27603540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoplastic thrombocytopenia and platelet transfusion: therapeutic goals.
    Karakatsanis SJ; Papadatos SS; Syrigos KN
    Hosp Pract (1995); 2019 Feb; 47(1):16-23. PubMed ID: 30409035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The definition of refractoriness to platelet transfusions.
    Bishop JF; Matthews JP; Yuen K; McGrath K; Wolf MM; Szer J
    Transfus Med; 1992 Mar; 2(1):35-41. PubMed ID: 1308461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.